1-6 of 6
Henning Schade
Close
Sort by
Journal Articles

Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Sumit Madan, Caitlin L. Costello, Brea Lipe, Andrew J. Cowan, Eva Medvedova, Jens Hillengass, P. Leif Bergsagel, Xavier Leleu, Cyrille Touzeau, Daniel Morillo, Albert Oriol, Raya Mawad, Henning Schade, Salomon Manier, Yifah Yaron, Banmeet Anand, Al-Ola Abdallah
Journal: Blood
Blood (2023) 142 (Supplement 1): 1012.
https://doi.org/10.1182/blood-2023-182345
Published: 2023
Journal Articles

Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

Al-Ola Abdallah, Andrew J Cowan, Xavier Leleu, Cyrille Touzeau, Brea Lipe, Eva Medvedova, Caitlin Costello, Jens Hillengass, P. Leif Bergsagel, Raya Mawad, Henning Schade, Daniel Morillo Giles, Albert Oriol, Yifah Yaron, Patrick P Ng, Sumit Madan
Journal: Blood
Blood (2022) 140 (Supplement 1): 7284–7285.
https://doi.org/10.1182/blood-2022-159665
Published: 2022
Journal Articles

A Phase II Single Arm Study of Nivolumab As Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Hodgkin Lymphoma at Risk of Relapse or Progression

Carlos Bachier, Henning Schade, Behyar Zoghi, Aravind Ramakrishnan, Nirav N. Shah
Journal: Blood
Blood (2021) 138 (Supplement 1): 2455.
https://doi.org/10.1182/blood-2021-148139
Published: 2021
Journal Articles

An Interim Report on a Phase 1/2 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC ® ) Targeting B Cell Maturation Antigen for the Treatment of Relapsed/Refractory Multiple Myeloma

Sumit Madan, Al-Ola Abdallah, Andrew J. Cowan, William I. Bensinger, Jens Hillengass, Xavier Leleu, Eva Medvedova, Caitlin Costello, Brea Lipe, Henning Schade, Rajneesh Nath, Liping Laura Sun
Journal: Blood
Blood (2021) 138 (Supplement 1): 1654.
https://doi.org/10.1182/blood-2021-148176
Published: 2021
Journal Articles

HPN217-3001: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217, a Bcma-Targeting T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma

Henning Schade, MD, Sumit Madan, MD, Eva Medvedova, MD, Rajneesh Nath, MD, Lisa Knapp, Bryan Lemon, PhD, Liping Laura Sun, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 10.
https://doi.org/10.1182/blood-2020-136012
Published: 2020
Journal Articles

Similar Dynamics Of Intra Apheresis Autologous CD34+ Recruitment and Collection Efficiency In Patients Undergoing Mobilization With Or Without Plerixafor

Henning Schade, MD, Yubin Kang, MD., Chhabra Saurabh, MD, Robert K Stuart, Kathy H Edwards, PharmD, Cindy Kramer, RN, BSN, OCN, Mollie Schneider, RN, BSN, Amanda Littleton, RN, BSN, Katie B Shoptaw, RN, BSN, MSN, Luciano J Costa, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 904.
https://doi.org/10.1182/blood.V122.21.904.904
Published: 2013